Fulcrum Therapeutics (FULC) Price & Analysis

Compare

494 Followers

FULC Stock Chart & Stats

Day’s Range― - ―

52-Week Range$2.32 - $10.13

Previous CloseN/A

Volume345.04K

Average Volume (3M)866.18K

Market Cap

$372.15M

Enterprise Value$223.76M

Total Cash (Recent Filing)$214.11M

Total Debt (Recent Filing)$7.57M

Price to Earnings (P/E)―

Beta1.70

Next Earnings

Nov 12, 2025

EPS Estimate

-0.29

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.28

Shares Outstanding54,091,587

10 Day Avg. Volume1,505,807

30 Day Avg. Volume866,180

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.60

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-2.74

Forecast

1Y Price Target

$9.86

Price Target Upside44.79% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say

Clinical Trial ResultsFULC reported positive 12mg dose cohort data from the Phase 1b PIONEER study demonstrating encouraging efficacy across multiple metrics.

Investor InterestThere is growing investor interest in FULC’s oral small molecule approach, as exhibited by FULC’s recent strength.

Stock PerformanceThe stock has more room to run, especially with growing scarcity value in the SCD space.

Bears Say

Patient ResponseThere is a downside risk that more therapy-unresponsive patients may not replicate the positive response seen in previous cohorts.

Safety ConcernsThere are consistent concerns from doctors regarding the safety of pociredir, which caps the company's stock upside despite recent price increases.

Trial EligibilityFulcrum Therapeutics had to tighten its eligibility criteria for trials in response to FDA's clinical hold due to potential malignancy risks.

Fulcrum Therapeutics News

H.C. Wainwright upgrades Fulcrum to Buy on sickle cell data

H.C. Wainwright upgraded Fulcrum Therapeutics (FULC) to Buy from Neutral with a price target of $12, up from...

10d ago

FULC

Fulcrum Therapeutics upgraded to Buy from Neutral at H.C. Wainwright

H.C. Wainwright upgraded Fulcrum Therapeutics (FULC) to Buy from Neutral with a price target of $12, up from...

10d ago

FULC

Fulcrum Therapeutics price target raised to $15 from $12 at Oppenheimer

Oppenheimer raised the firm’s price target on Fulcrum Therapeutics (FULC) to $15 from $12 and keeps an Outperform...

10d ago

FULC

Fulcrum Therapeutics’ pociredir shows efficacy in sickle cell disease

Fulcrum Therapeutics (FULC) reported positive results from the 12 mg dose cohort of the Phase 1b PIONEER trial...

10d ago

FULC

Fulcrum Therapeutics reports Q2 EPS (28c), consensus (29c)

Reports Q2 revenue $0 vs. $80M last year. As of June 30, cash, cash equivalents, and marketable securities...

10d ago

FULC

Fulcrum Therapeutics initiated with Early-Stage Biotech at Goldman Sachs

Goldman Sachs analyst Corinne Johnson started Fulcrum Therapeutics (FULC) with an Early-Stage Biotech rating. Published first on TheFly...

29d ago

FULC

Fulcrum Therapeutics Reports Q2 2025 Financial Results

Fulcrum Therapeutics ( ($FULC) ) has released its Q2 earnings. Here is a breakdown of the information Fulcrum...

2d ago

FULC

Promising Potential of Fulcrum Therapeutics’ Pociredir: A Buy Rating Backed by Positive Phase 1b Study Results

Analyst Joseph Schwartz of Leerink Partners reiterated a Buy rating on Fulcrum Therapeutics, retaining the price target of...

8d ago

FULC

Buy Rating for Fulcrum Therapeutics: Promising Potential of Pociredir in Sickle Cell Disease Treatment

Fulcrum Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Andrew Fein from...

10d ago

FULC

Fulcrum Therapeutics Announces Promising Phase 1b Trial Results

Fulcrum Therapeutics ( ($FULC) ) has provided an announcement. On July 29, 2025, Fulcrum Therapeutics announced promising results...

10d ago

FULC

Fulcrum Therapeutics price target raised to $6 from $2 at BofA

BofA raised the firm’s price target on Fulcrum Therapeutics (FULC) to $6 from $2 and keeps an Underperform...

1M ago

FULC

Cautious Outlook on Fulcrum Therapeutics Amid Safety Concerns and Narrowed Trial Focus

Bank of America Securities analyst Tazeen Ahmad reiterated a Sell rating on Fulcrum Therapeutics (FULC – Research Report)...

1M ago

FULC

Fulcrum Therapeutics Elects New Directors at Annual Meeting

Fulcrum Therapeutics ( ($FULC) ) has provided an update. At the 2025 annual meeting held on June 26,...

1M ago

FULC

Fulcrum Therapeutics price target raised to $9 from $6 at Piper Sandler

Piper Sandler analyst Edward Tenthoff raised the firm’s price target on Fulcrum Therapeutics (FULC) to $9 from $6...

2M ago

FULC

FULC FAQ

What was Fulcrum Therapeutics’s price range in the past 12 months?

Fulcrum Therapeutics lowest stock price was $2.31 and its highest was $10.13 in the past 12 months.

What is Fulcrum Therapeutics’s market cap?

Fulcrum Therapeutics’s market cap is $372.15M.

When is Fulcrum Therapeutics’s upcoming earnings report date?

Fulcrum Therapeutics’s upcoming earnings report date is Nov 12, 2025 which is in 96 days.

How were Fulcrum Therapeutics’s earnings last quarter?

Fulcrum Therapeutics released its earnings results on Jul 29, 2025. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.29 by $0.01.

Is Fulcrum Therapeutics overvalued?

According to Wall Street analysts Fulcrum Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Fulcrum Therapeutics pay dividends?

Fulcrum Therapeutics does not currently pay dividends.

What is Fulcrum Therapeutics’s EPS estimate?

Fulcrum Therapeutics’s EPS estimate is -0.29.

How many shares outstanding does Fulcrum Therapeutics have?

Fulcrum Therapeutics has 54,091,587 shares outstanding.

What happened to Fulcrum Therapeutics’s price movement after its last earnings report?

Fulcrum Therapeutics reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.29. Following the earnings report the stock price went down -2.817%.

Which hedge fund is a major shareholder of Fulcrum Therapeutics?

Currently, no hedge funds are holding shares in FULC

Fulcrum Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-30.00%

Trailing 12-Months

Asset Growth

-22.23%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Fulcrum Therapeutics

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Fulcrum Therapeutics (FULC) Earnings & Revenues

Historic Earnings Reports

FULC Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects a generally positive outlook for Fulcrum Therapeutics. The company reported significant progress in clinical trials, particularly with their PIONEER trial for sickle cell disease, and financial improvements due to decreased expenses. However, the decrease in cash reserves and net loss are points of concern. Overall, the highlights outweigh the lowlights, suggesting a positive sentiment.View all FULC earnings summaries

FULC Stock 12 Month Forecast

Average Price Target

$9.86

▲(44.79% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","9":"$9","16":"$16","5.5":"$5.5","12.5":"$12.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$15.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9.86,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.86</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,5.5,9,12.5,16],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.84,7.467692307692308,8.095384615384615,8.723076923076922,9.350769230769231,9.978461538461538,10.606153846153845,11.233846153846153,11.861538461538462,12.489230769230769,13.116923076923076,13.744615384615384,14.372307692307691,{"y":15,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.84,7.072307692307692,7.304615384615384,7.536923076923077,7.769230769230769,8.00153846153846,8.233846153846153,8.466153846153846,8.698461538461538,8.93076923076923,9.163076923076922,9.395384615384614,9.627692307692307,{"y":9.86,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.84,6.6984615384615385,6.556923076923077,6.415384615384616,6.273846153846153,6.132307692307692,5.990769230769231,5.849230769230769,5.707692307692308,5.566153846153846,5.424615384615384,5.283076923076923,5.141538461538461,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.33,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.31,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.01,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.55,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.6,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.21,"date":1730419200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.88,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4.7,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.96,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.59,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.38,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.96,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.84,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >